Welcome to Bristol-Myers Squibb Australia.
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb Australia aims to deliver on its commitments: to our patients and customers, to our employees, to our communities, and to our environment.
Visit our global website to find out more about Bristol-Myers Squibb worldwide.www.bms.com
2 May 2017: Bristol-Myers Squibb Australia supports The Bridge Program
24 November 2016: Opdivo (nivolumab) approved for advanced kidney cancer.
3 November 2016: New BMS patient resource; a guide to immuno-oncology.
1 May 2016: Opdivo (nivolumab) listed on the PBS for the treatment of advanced melanoma.
29 March 2016: New BMS guides published about access to medicines in Australia.
18 March 2016: Opdivo (nivolumab) approved for advanced non squamous non-small cell lung cancer
1 March 2016: Daklinza (daclatasvir) listed on the PBS for chronic hepatitis C
January 2016: Immuno-oncology agent Opdivo (nivolumab) approved for advanced melanoma & lung cancer
9 June 2015: BMS Australia- Best employer 3rd year running
- Case Study